key: cord-0428661-ttol25y2
authors: Hohl, C. M.; Rosychuk, R. J.; Hau, J. P.; Hayward, J.; Landes, M.; Yan, J. W.; Ting, D. K.; Welsford, M.; Archambault, P. M.; Mercier, E.; Chandra, K.; Davis, P.; Vaillancourt, S.; Leeies, M.; Small, S.; Morrison, L. J.; Network, Canadian COVID-19 Emergency Department Rapid Response
title: TREATMENTS, RESOURCE UTILIZATION, AND OUTCOMES OF COVID-19 PATIENTS PRESENTING TO EMERGENCY DEPARTMENTS ACROSS PANDEMIC WAVES: AN OBSERVATIONAL STUDY BY THE CANADIAN COVID-19 EMERGENCY DEPARTMENT RAPID RESPONSE NETWORK (CCEDRRN)
date: 2021-08-01
journal: nan
DOI: 10.1101/2021.07.30.21261288
sha: 5d6fd9ed0148b23996e551afb13ad9629a8c09da
doc_id: 428661
cord_uid: ttol25y2

Background: Treatment strategies for coronavirus disease 2019 (COVID-19) evolved between pandemic waves. Our objective was to compare treatments, acute care resource utilization, and outcomes of COVID-19 patients presenting to Emergency Departments across two pandemic waves. Methods: This observational study enrolled consecutive eligible COVID-19 patients presenting to 46 Emergency Departments participating in the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) between March 1 and December 31, 2020. We collected data by retrospective chart review. Our primary outcome was in-hospital mortality. We used logistic regression modeling to assess the impact of pandemic wave on outcomes. Results: We enrolled 9,967 patients in 8 provinces, 3,336 from the first and 6,631 from the second wave. Patients in the second wave were younger, fewer met criteria for severe COVID-19, and more were discharged from the Emergency Department. Adjusted for patient characteristics and disease severity, steroid use increased (odds ratio [OR] 8.0; 95% confidence interval [CI] 6.4 -- 10.0), while the use of invasive mechanical ventilation decreased (OR 0.5; 95%CI 0.4 -- 0.6) in the second wave. After adjusting for differences in patient characteristics and disease severity, the odds of hospitalization (OR 0.7; 95%CI 0.6 -- 0.8) and critical care admission (OR 0.6; 95%CI 0.4 -- 0.7) decreased, while mortality remained unchanged (OR 1.0; 95%CI 0.7-1.4). Interpretation: In patients presenting to Canadian acute care facilities, rapid uptake of steroid therapy was evident. Mortality was stable despite lower critical care utilization in the second wave.

COVID-19 continues to place a strain on acute care hospitals around the world. Early reports from the first wave of the pandemic were critical in allowing clinicians to gain an understanding of a new disease entity,(1-6) but reflected convenience samples of patients with more severe disease and typical presentations due to limited testing capacity. (7) Most studies omitted Emergency Department (ED) utilization,(1-6) even though EDs are the first point of contact in the acute care system for many with COVID-19, where critical admission and discharge decisions have to be made.

Early in the pandemic many patients were treated with experimental therapies such as hydroxychloroquine, chloroquine, ritonavir/lopinavir, or ivermectin based on anecdotal evidence or inconclusive observational studies, some of which have been disproven. (8) (9) (10) While high-quality randomized controlled trials identified effective therapies and clear indications for their use, (11) (12) (13) others remain unsupported by high quality evidence. (14) (15) (16) Understanding changing treatments and resource utilization patterns is important to understanding the uptake of evidence-based therapies into clinical practice, and evaluating resource utilization and patient outcomes over time. These observations may guide jurisdictions with continued resource allocation challenges in future pandemic waves.

The Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN, pronounced "sedrin") is a national collaboration that harmonized data collection on consecutive COVID-19 cases in 50 EDs across 8 provinces (https://canadiancovid19registry.org/). (17) CCEDRRN's goal is to generate real-world high-quality observational studies to evaluate and inform the pandemic response.

The main objective of this study was to compare treatments, acute care resource utilization, and outcomes of COVID-19 patients presenting to EDs across the first two pandemic waves.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.30.21261288 doi: medRxiv preprint

This pan-Canadian observational study enrolled consecutive eligible COVID-19 patients who presented to the EDs of 46 participating acute care hospitals between March 1 and December 31, 2020 . (17) The research ethics boards of participating institutions reviewed and approved the study protocol with a waiver of informed consent for patient enrollment. Patient partners with lived experience from geographically distributed locations across the country were engaged from study inception to completion. All study sponsors were not-for profit organizations, and had no role in study design, data collection, analysis, interpretation, or writing of this manuscript. All authors had access to study data, and vouch for this manuscript.

Research assistants screened institutional or provincial medical microbiology testing lists for nucleic acid amplification tests (NAATs) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and lists of presenting complaints or discharge diagnoses for consecutive eligible patients. (17) We excluded data from two sites that were unable to initiate data entry in 2020, and two sites that were unable to demonstrate >99% compliance with patient enrollment to ensure an unbiased sample.

We included all COVID-19 patients presenting to the EDs of participating sites, who were seen by an emergency physician, and whose medical record review was complete at the time of the data cut ( Figure 1 ). We excluded patients tested in the context of an elective admission as part of a preadmission checklist (e.g., planned hip revision), who were never seen by an emergency physician (e.g., seen directly by a consultant), and those who acquired COVID-19 in-hospital.

We defined confirmed COVID-19 as patients presenting with ongoing COVID-19 symptoms and a positive nucleic acid amplification test (NAAT) for severe acute respiratory syndrome coronavirus-2 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.30.21261288 doi: medRxiv preprint (SARS-CoV-2) obtained 14 days prior to, or after their ED arrival. This allowed us to capture patients who were diagnosed in the community and subsequently presented to the ED, and those with early false negative tests. We included patients presenting with COVID-19 symptoms and diagnosed with "confirmed COVID-19" to capture patients who were transferred into a CCEDRRN hospital whose NAAT at the sending site could not be confirmed, and patients who were presumed by treating clinicians to have COVID-19 despite negative NAATs.

We defined repeat COVID infections as cases in whom SARS-CoV-2 was isolated on two ED visits at least 90 days apart, based on reports of the longest duration of viral shedding reported. (18) (19) (20) We defined a wave as a period of sustained acceleration in cases followed by a period of sustained deceleration in cases on the World Health Organization (WHO) dashboard for Canada. Based on this, we allocated patients to the first wave if they presented between March 1 and June 30, 2020, and to the second wave if they presented between July 1 and December 31, 2020.

We defined presentations for severe COVID-19 according to WHO age-based criteria. (21) For adults, criteria for severe COVID-19 were met if the patient had an oxygen saturation of <90% on room air, a respiratory rate >30 breaths per minute, or signs of severe respiratory distress documented in the ED medical record.

Trained research assistants abstracted demographic and social, level of care, clinical, treatment, diagnostic and outcome variables from clinical records using standardized forms. We adhered to a data quality protocol and implemented data verification and quality checks to ensure high data quality. (17) All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We calculated the seven-day moving average incident COVID-19 cases per 100,000 population for every health region included in the study. (22) We mapped every patient to the seven-day moving average incident COVID-19 case count of their health region using their postal code of residence and index ED visit date. As publicly available incident COVID-19 case data were not available for the early pandemic (0.1% of values were missing), we imputed values for the first five weeks of the pandemic by modeling reported COVID-19 over time using linear interpolation. (22) 

Our primary outcome was in-hospital mortality. Secondary outcomes included treatments, hospital and ICU admissions, and ED revisits and readmissions at seven and 30 days.

We summarized patient characteristics, treatments, and outcomes for each pandemic wave using descriptive statistics. We assessed wave differences with t-tests or analysis of variance (ANOVA) for continuous variables and chi-square tests for categorical variables. Separate logistic regressions with a random effect for patients modeled the associations between pandemic wave and the outcomes of interest. We considered different adjustments to provide an understanding of the incremental association between factors and the pandemic wave: (1) patient (age, sex, comorbidity, tobacco and illicit substance use) and presentation characteristics (arrival mode, arrival from, and WHO severe disease) recorded at the index ED visit, and (2) the variables in (1) as well as the seven-day moving average incident COVID-19 cases to account for changes in prognosis due to hospital burden.(23) We entered age and the seven-day moving average incident COVID-19 cases as continuous variables into our models; other variables were categorical. We conducted subgroup analyses on patients with severe COVID, pregnant patients, those reporting unstable housing, and those requiring invasive mechanical ventilation. We provided estimates with 95% confidence intervals (CIs). To ensure patient privacy, a cell size restriction policy prohibited us from reporting counts of less than five. A P-value less than All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We enrolled 9,967 COVID-19 patients, of whom 3,336 (33.5%) presented in the first and 6,631 (66.5%) in the second wave (Figures 1 & 2 ). Of these, 3,319 were enrolled in Quebec (33.3%), 2,868

in Alberta (28.8%) and 2,458 in British Columbia (25.6%). In all but 80 (0.8%) patients, a NAAT confirmed the COVID-19 diagnosis. Follow-up time was 30 days for discharged patients and between 30 and 229 days for admitted patients.

Patients presenting to acute care hospitals differed between waves (Table 1) . During the second wave, patients were younger (mean age 53.2 versus 59.4 years old) with a similar proportion being female (49.2% versus 49.7%), and fewer comorbidities compared to the first wave. In the second wave, patients were less likely to arrive from long-term care (5.6% versus 18.3%), report an occupational exposure (2.3% versus 8.7%), travel-related infection (1.9% versus 6.8%) or an institutional exposure (7.5% versus 18.6%). Fewer patients met criteria for severe disease in the second wave (11.8% versus 17.0%).

Steroids were used more frequently (28.0% versus 9.5%, p<0.0001), and antimalarials (0.3% versus 9.0%, p<0.0001) and antivirals (1.5% versus 6.7%, p<0.0001) less frequently in the second wave (Table 2 ). Differences persisted after adjustment for baseline patient characteristics and disease severity (Tables 3a & b) . A smaller proportion of patients were mechanically ventilated (3.7% versus 7.0%, p<0.0001) in the second wave versus the first, which also persisted after adjustment (OR 0.51; 95% CI 0.41 -0.64). Even though patients were intubated at the same time after the onset of COVID-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A greater proportion of patients were discharged directly from EDs in the second wave (61.3% versus 47.2%, p<0.0001; Table 4a ). While a slightly higher proportion of patients revisited the ED within seven days (6.9% versus 5.8%, p=0.025), revisits were the same within 30 days (9.0% versus 8.8%, p=0.76) but more likely to result in admissions (8.2% versus 6.1%, p=0.008; Table 4b) in the second wave. In both waves a small proportion of patients died in the ED (0.5% versus 0.2%, p=0.016).

In the second wave, hospital admissions were shorter (mean 11.7 versus 15.6 days, p<0.0001; Table   4b ), yet readmissions after hospital discharge were rare and similar across both waves (Appendix Table 2 ). In the second wave, fewer patients were admitted to critical care (7.7% versus 12.6%, p<0.0001; Table 2 ) and spent fewer days on average in critical care (10.5 versus 15.6 days, p<0.0001; Table 4b ). These differences persisted after adjustment for differences in patient characteristics, disease severity, and the seven-day moving average incident COVID-19 cases (Table 5) . Crude mortality was lower in the second wave (6.1% versus 8.5%; odds ratio [OR] 0.69, 95% CI 0.59-0.82), but disappeared after adjusting for patient characteristics, disease severity, and the seven-day moving average incident COVID-19 cases (OR 1.0; 95% CI 0.74-1.37).

During the study period, fewer than five of 9,967 patients (<0.05%, 95% CI 0.0002-0.0012%) revisited a participating ED with a NAAT-confirmed re-infection greater than 90 days after their first visit. Among 119 pregnant patients, 28 (0.2%, 95% CI 0.2-0.3%) required admission, fewer than five (<0.05%, 95% CI: 0.013-0.09%) required mechanical ventilation, and none died. Among 176 (1.7%, 95% CI: 0.015-0.020%) patients reporting unstable housing (homeless, shelter, or single room All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.30.21261288 doi: medRxiv preprint occupancy), the proportion admitted was 50.6% (95% CI: 43.2-57.9%), and fewer than five (<5%, 95% CI: 0.84-5.93%) died.

Our objective was to compare treatments, acute care utilization, and outcomes of COVID-19 patients presenting to acute care hospitals between pandemic waves. We found differences in patient characteristics between the first two waves reflecting public health measures to protect seniors and reduce travel. (24) We observed rapid uptake of evidence-based therapies and declining use of disproven therapies, indicating rapid translation of research evidence into practice. We observed decreasing hospital and critical care resource utilization over time, and less invasive mechanical ventilation with no adverse effect on mortality.

Unlike previous studies that were limited to single sites, (25) (26) (27) we enrolled patients in urban and rural, and academic and non-academic sites across Canada. We captured all COVID-19 patients, including vulnerable patients who are typically unable to provide informed consent (e.g., those with language barriers). Thus, we are confident that our sample is representative of COVID-19 patients who presented to Canadian EDs during the study period. We ascertained the outcomes of all enrolled patients, without censoring of patient outcomes at 28 or 30 days, or at the time of analysis, as was commonly done in early studies leading to incomplete outcome ascertainments. (14, 28) We observed changes to the frequency, initiation, and duration of invasive mechanical ventilation over the study period associated with decreasing critical care resource utilization, consistent with other studies. (29) Early in the pandemic, non-evidence based criteria had been widely disseminated recommending early endotracheal intubation.(30) These recommendations were widely adopted despite lack of supporting evidence. While ventilation strategies continue to lack high-quality supportive evidence, this guidance All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.30.21261288 doi: medRxiv preprint has been questioned. (14) (15) (16) Our study does not allow for causal inferences, but documented less frequent invasive mechanical ventilation, later intubations, and a shorter duration of invasive mechanical ventilation in the second wave. These were associated with reduced critical care resource utilization and no adverse impacts on mortality.

In contrast to other studies, mortality was stable in our cohort after adjustment for differences in baseline patient characteristics and disease severity. Some studies that used administrative data observed decreasing mortality in Spring 2020, before any evidence-based treatments had been identified. (6, 31) While some hypothesized that these observations were the result of improved clinical care as clinicians gained experience treating COVID-19, it is possible that these findings were the result of ascertainment bias. (7) Testing restrictions during the first wave meant that only the sickest COVID-19 patients were recognized and tested, which could have introduced systematic error. (32) Studies describing risk factors for mortality have consistently pointed toward age and respiratory parameters as the two most important predictors for deterioration and mortality in COVID-19. (28) Administrative database studies are unable to capture these clinical variables, and thus are unable to adjust for differences in disease severity at presentation. As a result, it is possible that ascertainment bias and residual confounding explain the early drop in mortality observed in administrative database studies. (6) In the early pandemic, residents of long-term care were tested more liberally than healthier populations. Oversampling of long-term care residents early on may have increased the observed mortality risk in the first wave compared to the second due to competing risks.(31) These differences may explain the observed differences in mortality trends across studies. In contrast, CCEDRRN sites were able to enroll consecutive patients across both waves when testing resources were adequate and used clinical data to adjust for baseline differences.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We were unable to link our data with genomic data to identify variants of concern which may be associated with higher in-hospital mortality.(33) While, variants of concern were limited in Canada during the study period, we plan to investigate this in future studies.

We captured data retrospectively, and thus were limited to what was documented in medical records.

We validated retrospectively collected data elements at several sites by comparing retrospectively collected data with prospectively collected data. (17) We were unable to link our data with genomic data to identify variants of concern which may be associated with higher in-hospital mortality. (33) However, there was limited circulation of variants of concern in Canada during the study period. We removed data from four sites making the study less generalizable, but instead ensured the integrity of our sample of consecutive cases to avoid selection bias.

Our study documents rapid uptake of evidence during the COVID-19 pandemic, both for proven and disproven therapies, and efficiencies in resource utilization over time with increased rates of ED discharges and lower hospital and critical care resource use over time. This, indicates that advances in clinical decision-making and treatments created efficiencies, allowing health systems to safely care for greater numbers of patients.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.30.21261288 doi: medRxiv preprint

NS-Secondary Assessment Centre in NS closed in the first wave; ON-Toronto Western joined CCEDRRN in the second wave. We excluded four of 50 CCEDRRN sites. Two sites only started collecting data in 2021, and two sites had incomplete study trackers and were unable to demonstrate >99% compliance with patient enrollment. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. days of their admission (d) 80 patients presented with COVID-19 symptoms who were diagnosed as "confirmed COVID-19" with no documented NAAT in the medical record we were able to review, and whose first positive NAAT was no later than 14 days after arrival.

-391 patients (428 visits) presented outside the study period -47,134 patients (52,491 visits) tested COVID negative All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ED=Emergency Department * Unstable housing includes homeless, shelter, single room occupancy ** The denominator for symptom duration is 2,823 for wave 1, and 5,106 for wave 2. *** We defined presentations for severe COVID-19 disease according to WHO age-based criteria. For adults, criteria for severe COVID-19 were met if the patient had an oxygen saturation of <90% on room air, a respiratory rate >30 breaths per minute, or signs of severe respiratory distress documented in the ED medical record.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 1 We excluded 960 patients from 4 study sites that did not have enrollment in both waves. § Adjusted for age, sex, existing comorbidities (moderate or severe liver disease, hypertension, diabetes, congestive heart failure, coronary artery disease, asthma, chronic lung disease, active cancer, and obesity), WHO severe disease, arrival from, ambulance arrival mode, smoking status, and illicit substance use. * Reference category ** Did not adjust for moderate or severe liver disease due to collinearity. 1 We excluded 960 patients from 4 study sites that did not have enrollment in both waves. § Adjusted for age, sex, existing comorbidities (moderate or severe liver disease, hypertension, diabetes, congestive heart failure, coronary artery disease, asthma, chronic lung disease, active cancer, and obesity), arrival from, ambulance arrival mode, smoking status, and illicit substance use * Reference category ** Did not adjust for moderate or severe liver disease due to collinearity All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. § Adjusted for age, sex, existing comorbidities (moderate or severe liver disease, hypertension, diabetes, congestive heart failure, coronary artery disease, asthma, chronic lung disease, active cancer, and obesity), WHO severe disease, arrival from, ambulance arrival mode, smoking status, and illicit substance use. * Reference category All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2021. ;

Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study

Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area

Patients in hospital with laboratory-confirmed COVID-19 in a network of Canadian acute care hospitals

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data

Severe underestimation of COVID-19 case numbers: effect of epidemic growth rate and test restrictions

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial

Remdesivir for the Treatment of Covid-19 -Final Report

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Metaanalysis

Dexamethasone in Hospitalized Patients with Covid-19

Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study

Management of COVID-19 Respiratory Distress

Caution about early intubation and mechanical ventilation in COVID-19. Ann Intensive Care

Development of the Canadian COVID-19 Emergency Department Rapid Response Network population-based registry: a methodology study

The duration of viral shedding of discharged patients with severe COVID-19

Asymptomatic infection and atypical manifestations of COVID-19: Comparison of viral shedding duration

Interim Guidance on Duration of Isolation and Precautions for Adults with COVID-19

World Health Organization. COVID-19 Clinical management: living guidance

Esri Canada. COVID-19 Canada

Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic

Individual and community-based measures to mitigate the spread of COVID-19 in Canada

Characteristics and outcomes in hospitalized COVID-19 patients during the first 28 days of the spring and autumn pandemic waves in Milan: An observational prospective study

First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus

Longitudinal Changes in COVID-19 Associated In-Hospital Mortality. medRxiv

Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score

Trends in Intensive Care for Patients with COVID-19 in England, Wales, and Northern Ireland

Expert Recommendations for Tracheal Intubation in Critically ill Patients with Noval Coronavirus Disease

Second wave mortality among patients hospitalised for COVID-19 in Sweden: a nationwide observational cohort study

Decreased COVID-19 Mortality-A Cause for Optimism

Increased mortality among individuals hospitalised with COVID-19 during the second wave in South Africa. medRxiv